Product Pathways - Tyrosine Kinase/ Adaptors
Phospho-Ret (Tyr905) Antibody #3221
| Applications | Reactivity | Sensitivity | MW (kDa) | Source |
|---|---|---|---|---|
| W IP | H Dm | Endogenous | 175 | Rabbit |
Applications Key:
W=Western Blotting
IP=Immunoprecipitation
Reactivity Key:
H=Human
Dm=D. melanogaster
Species cross-reactivity is determined by Western blot.
Protocols
Specificity / Sensitivity
Phospho-Ret (Tyr905) Antibody detects endogenous levels of Ret only when phosphorylated at tyrosine 905.
Source / Purification
Polyclonal antibodies are produced by immunizing animals with a synthetic phosphopeptide corresponding to residues surrounding Tyr905 of human Ret. Antibodies are purified by protein A and peptide affinity chromatography.
Western Blotting
Western blot analysis of recombinant human GST-Ret (His658-Asp1110) and extracts from the TT human medullary thyroid carcinoma cell line using Phospho-Ret (Tyr905) Antibody.
Western Blotting
Western blot analysis of recombinant human GST-Ret (His658-Asp1110), untreated or λ phosphatase-treated, using Phospho-Ret (Tyr905) Antibody (upper) and Ret Antibody #3220 (lower).
Background
The Ret proto-oncogene (c-Ret) is a receptor tyrosine kinase that functions as a multicompetent receptor complex in conjunction with other membrane-bound ligand-binding GDNF family receptors (1). Ligands that bind the Ret receptor include the glial cell line-derived neurotropic factor (GDNF) and its congeners neurturin, persephin and artemin (2-4). Alterations in the corresponding Ret gene are associated with diseases including papillary thyroid carcinoma, multiple endocrine neoplasia (type 2A and 2B), familial medullary thyroid carcinoma and a congenital developmental disorder known as Hirschsprung’s disease (1,3). The Tyr905 residue located in the Ret kinase domain plays a crucial role in Ret catalytic and biological activity. Substitution of Phe for Tyr905 dramatically inhibits Ret autophosphorylation activity (5).
- Airaksinen, M.S. et al. (1999) Mol. Cell. Neurosci. 13, 313-325.
- Takahashi, M. et al. (1989) Oncogene 4, 805-806.
- Manie, S. et al. (2001) Trends Genet. 17, 580-589.
- Tallini, G. and Asa, S. (2001) Adv. Anat. Pathol. 8, 345-354.
- Iwashita, T. et al. (1999) Oncogene 18, 3919-3922.
Application References
- Mologni, L. et al. (2006) J Mol Endocrinol 37, 199-212. Applications: Western Blotting
- Strock, C. J. et al. (2003) CEP-701 and CEP-751 Inhibit Constitutively Activated RET Tyrosine Kinase Activity and Block Medullary Thyroid Carcinoma Cell Growth. Cancer Res. 63, 5559-5563. Applications: Western Blotting
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
Companion Products
- 3223 Ret (C31B4) Rabbit mAb
- 3220 Ret Antibody
- 7071 Phototope®-HRP Western Blot Detection System, Anti-rabbit IgG, HRP-linked Antibody
- 7074 Anti-rabbit IgG, HRP-linked Antibody
- 7720 Prestained Protein Marker, Broad Range (Premixed Format)
- 7727 Biotinylated Protein Ladder Detection Pack
- 7003 20X LumiGLO® Reagent and 20X Peroxide
This product is intended for research purposes only. The product is not intended to be used for therapeutic or diagnostic purposes in humans or animals.
